These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25797502)

  • 21. Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression.
    Andruska ND; Zheng X; Yang X; Mao C; Cherian MM; Mahapatra L; Helferich WG; Shapiro DJ
    Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4737-42. PubMed ID: 25825714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs.
    Nichols M; Cheng P; Liu Y; Kanterewicz B; Hershberger PA; McCarty KS
    Breast Cancer Res Treat; 2010 Apr; 120(3):761-8. PubMed ID: 19526339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
    O'Boyle NM; Barrett I; Greene LM; Carr M; Fayne D; Twamley B; Knox AJS; Keely NO; Zisterer DM; Meegan MJ
    J Med Chem; 2018 Jan; 61(2):514-534. PubMed ID: 28426931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion.
    JavanMoghadam S; Weihua Z; Hunt KK; Keyomarsi K
    Cell Cycle; 2016 Jun; 15(12):1579-90. PubMed ID: 27049344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, Synthesis, and Biological Evaluation of 2-(2-Bromo-3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole Derivatives as Possible Anti-Breast Cancer Agents.
    Ananth AH; Manikandan N; Rajan RK; Elancheran R; Lakshmithendral K; Ramanathan M; Bhattacharjee A; Kabilan S
    Chem Biodivers; 2020 Feb; 17(2):e1900659. PubMed ID: 31995280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and In Vitro Evaluation of Tetrahydroquinoline Derivatives as Antiproliferative Compounds of Breast Cancer via Targeting the GPER.
    Zacarías-Lara OJ; Méndez-Luna D; Martínez-Ruíz G; García-Sanchéz JR; Fragoso-Vázquez MJ; Bello M; Becerra-Martínez E; García-Vázquez JB; Correa-Basurto J
    Anticancer Agents Med Chem; 2019; 19(6):760-771. PubMed ID: 30451119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
    Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
    Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein arginine methyltransferase 6 enhances ligand-dependent and -independent activity of estrogen receptor α via distinct mechanisms.
    Sun Y; Chung HH; Woo AR; Lin VC
    Biochim Biophys Acta; 2014 Sep; 1843(9):2067-78. PubMed ID: 24742914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
    Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
    Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DESIGN, SYNTHESIS, MOLECULAR DOCKING AND ANTI-BREAST CANCER ACTIVITY OF NOVEL QUINAZOLINONES TARGETING ESTROGEN RECEPTOR α.
    Ahmed MF; Youns M; Belal A
    Acta Pol Pharm; 2016; 73(1):115-27. PubMed ID: 27008806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.
    Lloyd DG; Smith HM; O'Sullivan T; Knox AS; Zisterer DM; Meegan MJ
    Med Chem; 2006 Mar; 2(2):147-68. PubMed ID: 16787364
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
    J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Designer interface peptide grafts target estrogen receptor alpha dimerization.
    Chakraborty S; Asare BK; Biswas PK; Rajnarayanan RV
    Biochem Biophys Res Commun; 2016 Sep; 478(1):116-122. PubMed ID: 27462021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular docking, synthesis and anticancer activity of thiosemicarbazone derivatives against MCF-7 human breast cancer cell line.
    Sibuh BZ; Khanna S; Taneja P; Sarkar P; Taneja NK
    Life Sci; 2021 May; 273():119305. PubMed ID: 33675898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.
    Carr M; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
    J Enzyme Inhib Med Chem; 2016; 31(sup3):117-130. PubMed ID: 27476825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen-related Receptor β Reduces the Subnuclear Mobility of Estrogen Receptor α and Suppresses Estrogen-dependent Cellular Function.
    Tanida T; Matsuda KI; Yamada S; Hashimoto T; Kawata M
    J Biol Chem; 2015 May; 290(19):12332-45. PubMed ID: 25805499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
    Albanito L; Madeo A; Lappano R; Vivacqua A; Rago V; Carpino A; Oprea TI; Prossnitz ER; Musti AM; Andò S; Maggiolini M
    Cancer Res; 2007 Feb; 67(4):1859-66. PubMed ID: 17308128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis, structure-activity relationships and antagonistic effects in human MCF-7 breast cancer cells of flexible estrogen receptor modulators.
    Lloyd DG; Smith HM; O'Sullivan T; Zisterer DM; Meegan MJ
    Med Chem; 2005 Jul; 1(4):335-53. PubMed ID: 16789891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.